Ascletis Pharma has completed subject enrolment in its 13-week US Phase II study of ASC30 as a treatment for type 2 diabetes mellitus (T2DM).
The post Ascletis completes subject enrolment in Phase II ASC3 trial appeared first on Clinical Trials Arena.
The oldest millennials are turning 45 this year. The oldest Gen Xers are now 60. So how prepared will they be to thrive in the decades …
Rep. Jason Crow (D-Colo.) on Sunday criticized the Trump administration’s decision to withdraw 5,000 troops from Germany following a public spat with German Chancellor Friedrich Merz. …
Today’s export control authorities don't need a new screening strategy — they simply need to dust off the autopsy reports they already have.
في ظل الانتشار الواسع للمشروبات الغازية الداكنة اللون يحذر خبراء الصحة من آثارها المتراكمة على الكلى عند استهلاكها بشكل يومي